Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.
Because of high death rates in the past, patients with HIV-1 cannot obtain life insurance. We measured mortality rates in the Swiss HIV Cohort Study (SHCS) from 1997 to 2001 and compared them with those of the Swiss reference population. In patients who were successfully treated with highly active anti-retroviral therapy (HAART), and who were not also infected with the hepatitis C virus, excess death rates were below five per thousand per year. Patients with successfully treated cancer have much the same excess death rates but are not excluded from life insurance policies.
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality*; D015497:HIV-1; D006526:Hepatitis C / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D007352:Insurance, Life / Q000706:statistics & numerical data; D008297:Male; D009026:Mortality; D013557:Switzerland / Q000453:epidemiology; D016896:Treatment Outcome